Ipilimumab/nivolumabColitis: 2 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1735卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56776-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：160 / 160

相关论文

共 50 条

[41] Ipilimumab/pembrolizumabHepatitis: 2 case reports
Reactions Weekly, 2017, 1673 (1) : 217 - 217
[42] Ipilimumab/nivolumab/nivolumabColitis and lack of efficacy
Reactions Weekly, 2024, 2005 (1) : 469 - 469
[43] Ipilimumab/nivolumabHepatitis: 2 case reports
Reactions Weekly, 2017, 1665 (1) : 164 - 164
[44] Ipilimumab/nivolumabColitis, hyperthyroidism and type 1 diabetes mellitus: case report
Reactions Weekly, 2018, 1705 (1) : 174 - 174
[45] Ipilimumab/nivolumabAutoimmune encephalitis: 2 case reports
Reactions Weekly, 2019, 1782 (1) : 186 - 186
[46] Ipilimumab/nivolumabLack of efficacy: 2 case reports
Reactions Weekly, 2022, 1907 (1) : 269 - 269
[47] Dabrafenib/ipilimumab/trametinibColitis: 2 case reports
Reactions Weekly, 2016, 1583 (1) : 382 - 382
[48] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2020, 1790 (1) : 141 - 141
[49] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1676 (1) : 175 - 175
[50] Ipilimumab/nivolumab/pembrolizumabPneumonitis: 2 case reports
Reactions Weekly, 2022, 1917 (1) : 327 - 327

← 1 2 3 4 5 →